Katherine Rifiotis Slivensky

Associate

Chicago + 1.312.269.4124

Contacto:

Compartir

Katherine Rifiotis Slivensky joined Jones Day's New Lawyers Group (NLG) in 2025. The NLG provides new lawyers with the opportunity to explore various practice areas and approaches to law before selecting a specific focus. During their first year, participants may either concentrate on one discipline or rotate among several practices to gain broader experience.

Before attending law school, Katherine worked as a policy analyst at a Department of Energy nuclear physics laboratory and later joined the compliance team of a Fortune 500 financial services firm, where she focused on regulatory strategy and organizational risk management.

Experiencia

  • WESCO Distribution completes $1.5 billion Senior Notes offeringJones Day represented WESCO International, Inc., a leading provider of business-to-business distribution, logistics services and supply chain solutions, in connection with its $1.5 billion Rule 144A and Regulation S offering of Senior Notes, consisting of $650 million of 5.250% Senior Notes due 2031 and $850 million of 5.500% Senior Notes due 2034 by direct subsidiary of WESCO International, Inc.
  • WESCO Distribution completes $1.5 billion Senior Notes offeringJones Day represented WESCO International, Inc., a leading provider of business-to-business distribution, logistics services and supply chain solutions, in connection with its $1.5 billion Rule 144A and Regulation S offering of Senior Notes, consisting of $650 million of 5.250% Senior Notes due 2031 and $850 million of 5.500% Senior Notes due 2034 by direct subsidiary of WESCO International, Inc.
  • BioMarin acquires Amicus Therapeutics for $4.8 billionJones Day is advising BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) in its $4.8 billion acquisition of Amicus Therapeutics (Nasdaq: FOLD).
    •

    Antes del envío, por favor tenga en cuenta:

    la información contenida en www.jonesday.com es para uso general y no constituye asesoramiento legal. El envío y recepción de este correo electrónico no pretenden crear una relación abogado-cliente. La información que envíe a cualquier persona de nuestra Firma no tendrá carácter confidencial o privilegiado excepto en el caso de que estemos actúando en su representación. Si envía este correo electrónico, confirma que ha leído y comprendido este aviso.